The Week

Johnson & Johnson (JNJ) finished the week down 5.6% at $256.03, while the S&P 500 slipped just 0.27%, leaving JNJ about 5.33 percentage points behind the benchmark. The sell-off was steady: after opening Monday at $270.17 and touching an early high of $273.78, the stock drifted lower across the next four sessions, broke below $260 on Thursday, and closed Friday near the week’s low of $255.12. Weekly amplitude came to 6.91%. Average daily volume of 7.68m shares ran 17.52% above the 60-day median, pointing to distribution rather than a quiet drift.

Key Events

The week was heavy on clinical data. On Monday, Carvykti’s five-year remission data in early multiple myeloma added long-term evidence for the haematology franchise. On Tuesday, J&J presented data on IMAAVY® (nipocalimab-aahu) showing sustained disease control and improved daily function in generalised myasthenia gravis; the same evening, BofA raised its J&J price target but said it sees third-quarter earnings running 12% below Street estimates. Wednesday brought Q3 preview coverage with projections of in-line sales but a likely earnings miss. Later in the week, J&J released evidence from Neutrogena, Aveeno and Regaine, followed by ICOTYDE® (icotrokinra) data confirming two-year durability of skin clearance in difficult-to-treat plaque psoriasis, with the company positioning it as a first-line systemic therapy. The story, then, was one of steady pipeline updates against a backdrop of cautious earnings expectations.

Analyst Ratings

Across 24 institutions covering JNJ, 11 rate it buy, 5 overweight, 6 hold, 1 sell and 1 no opinion; the consensus recommendation is buy. The consensus target sits at $279.27, about 9.08% above the $256.03 close. The target range is wide, from $190 to $320, suggesting real disagreement: the low end implies roughly two-tenths downside while the high end implies about two-tenths upside. Within the pharmaceutical industry, JNJ ranks 5th out of 203 names, a relatively strong position.

The Week Ahead

The macro calendar starts the week: US S&P Global services PMI final and ISM non-manufacturing PMI land on Monday, followed by international trade data on Tuesday and weekly EIA crude and Cushing inventories on Wednesday. For JNJ itself, the key date is 13 October, when the company reports fiscal Q3 2026 results before the open. The market expects earnings per share of about $2.07 and revenue of about $25.3bn. With this week’s previews already flagging a possible earnings shortfall relative to Street forecasts, the Q3 print will be the main test of whether the recent pullback has fundamentally changed the narrative.

In Short

The week’s price action was weak—a high-volume decline that lagged the broad market—even as the company put out a string of solid clinical updates. The analyst backdrop remains constructive, with a consensus buy rating and a target roughly 9% above spot, but the latest session’s money flows were split: large-lot orders turned net buyers while small and medium orders were net sellers. At 7.26x price-to-book and 29.33x trailing earnings, the stock is not cheap within the pharma group. The next pivot is 13 October’s Q3 report, and whether it can close the gap between earnings expectations and what the market is currently pricing.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.